[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 13 of about 13
1. Tsuchiya T, Hagihara M, Shimakura Y, Ueda Y, Gansuvd B, Munkhbat B, Inoue H, Tazume K, Kato S, Hotta T: The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells. Int J Hematol; 2002 Jan;75(1):55-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The generation of immunocompetent dendritic cells from CD34+ acute myeloid or lymphoid leukemia cells.
  • The ability of CD34+ leukemic cells to differentiate to dendritic cells (DCs) was investigated in 18 acute myeloid leukemia (AML) and 4 lymphoid leukemia (ALL) patients.
  • In the AML patients, allostimulatory mature DCs were generated from 3 of 9 M0 or M1, 2 of 5 M2,2 of 4 M4 or M5, and 3 of 4 ALL (L2) cases.
  • B-cell (CD19), natural killer (NK)-cell (CD56), or T-cell (CD7) lineage markers, which were aberrantly expressed on the blasts, were rarely found on leukemic DCs at the end of the culture period, and myeloid (CD13, CD33), not lymphoid (CD10), markers were shown on ALL-derived DCs.
  • In Philadelphia chromosome-positive ALL or AML patients with t (8;21), DCs were confirmed to be of leukemic origin by fluorescence in situ hybridization analysis.
  • [MeSH-major] Dendritic Cells / immunology. Leukemia, Myeloid / pathology. Neoplastic Stem Cells / cytology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Acute Disease. Adolescent. Adult. Aged. Antigens, CD34 / analysis. Antigens, Differentiation / analysis. Bone Marrow / pathology. Cell Differentiation / drug effects. Cell Lineage. Female. Humans. Immunophenotyping. In Situ Hybridization, Fluorescence. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology. Male. Middle Aged. Philadelphia Chromosome. Proto-Oncogene Proteins / pharmacology. Receptor Protein-Tyrosine Kinases / pharmacology. T-Lymphocyte Subsets / immunology. Tumor Cells, Cultured / cytology. Tumor Cells, Cultured / drug effects. fms-Like Tyrosine Kinase 3

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2588-92 [8637918.001]
  • [Cites] J Immunol. 1996 Nov 1;157(9):3850-9 [8892615.001]
  • [Cites] Blood. 1998 Sep 1;92(5):1677-84 [9716596.001]
  • [Cites] J Exp Clin Cancer Res. 1998 Sep;17(3):251-8 [9894758.001]
  • [Cites] Curr Med Res Opin. 1999;15(4):321-6 [10640266.001]
  • [Cites] Immunol Rev. 1991 Dec;124:25-43 [1804779.001]
  • [Cites] Hum Immunol. 1997 Apr 1;53(2):216-23 [9129981.001]
  • [Cites] Immunity. 1995 Oct;3(4):459-73 [7584137.001]
  • [Cites] Blood. 1998 Apr 15;91(8):2760-71 [9531586.001]
  • [Cites] Eur J Immunol. 1999 Aug;29(8):2567-78 [10458772.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):1028-34 [10706120.001]
  • [Cites] Blood. 1998 Apr 1;91(7):2406-14 [9516140.001]
  • [Cites] Blood. 1998 Feb 1;91(3):977-83 [9446659.001]
  • [Cites] Cancer Res. 1995 Mar 1;55(5):1099-104 [7532543.001]
  • [Cites] Mol Diagn. 1996 Dec;1(4):305-313 [10462577.001]
  • [Cites] Blood. 1999 Sep 15;94(6):2048-55 [10477734.001]
  • [Cites] Leukemia. 1999 Feb;13(2):166-74 [10025889.001]
  • [Cites] Cancer Res. 2000 Apr 1;60(7):1895-900 [10766177.001]
  • [Cites] Blood. 1999 Oct 1;94(7):2293-300 [10498601.001]
  • [Cites] J Immunol. 1995 Jun 1;154(11):5851-61 [7538534.001]
  • [Cites] Ann Hematol. 2000 Jul;79(7):355-62 [10965783.001]
  • [Cites] J Immunol. 2000 Feb 1;164(3):1269-76 [10640740.001]
  • [Cites] Br J Haematol. 1998 Dec;103(3):763-71 [9858228.001]
  • [Cites] Leukemia. 1995 Feb;9(2):282-7 [7869765.001]
  • [Cites] Blood. 1999 Feb 1;93(3):780-6 [9920826.001]
  • [Cites] Hum Immunol. 2000 Jun;61(6):565-74 [10825585.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1178-83 [9448305.001]
  • [Cites] Science. 1999 Feb 19;283(5405):1183-6 [10024247.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1474-82 [11222396.001]
  • [Cites] J Leukoc Biol. 1999 Dec;66(6):909-14 [10614771.001]
  • [Cites] J Immunol. 2000 Jul 1;165(1):566-72 [10861097.001]
  • [Cites] Blood. 1998 May 15;91(10):3892-900 [9573027.001]
  • [Cites] J Immunol. 1997 Dec 1;159(11):5483-91 [9548488.001]
  • [Cites] J Immunol. 1999 Jun 1;162(11):6473-81 [10352262.001]
  • [Cites] J Leukoc Biol. 1992 Sep;52(3):274-81 [1387891.001]
  • [Cites] Stem Cells. 2000;18(2):139-47 [10742386.001]
  • [Cites] Nat Med. 1998 Mar;4(3):328-32 [9500607.001]
  • (PMID = 11843292.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antigens, Differentiation; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / FLT3 protein, human; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / fms-Like Tyrosine Kinase 3
  •  go-up   go-down


2. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Ohno R: [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group]. Gan To Kagaku Ryoho; 2000 Jul;27(8):1160-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of etoposide added to individualized induction therapy of adult acute myeloid leukemia--the JALSG-AML-92 Study. Japan Adult Leukemia Study Group].
  • A multicenter prospective randomized study was undertaken to assess the efficacy of etoposide added to the standard remission induction therapy for acute myeloid leukemia (AML).
  • Consecutively registered newly diagnosed adult AML patients were randomized to receive either daunorubicin (40 mg/m2/day x 4 or more), behenoyl cytarabine (200 mg/m2/day x 10 or more) and 6-mercaptopurine (70 mg/m2/day x 10 or more) (BH-AC-DM), or the same three drugs plus etoposide (100 mg/m2/day x 5) (BH-AC-EDM) for response-oriented individualized induction therapy.
  • M3 was excluded and M0 was included.
  • In conclusion, the present study failed to show any advantage of the addition of etoposide to the standard individualized induction therapy in adult AML, even among M4 and M5.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Etoposide / administration & dosage. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Aged. Aged, 80 and over. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Humans. Middle Aged. Prospective Studies


3. Pagano L, Pulsoni A, Mele L, Tosti ME, Cerri R, Visani G, Melillo L, Candoni A, Clavio M, Nosari A, Petti MC, Martino B, Mele A, Levis A, Allione B, Almici C, Equitani F, Leone G, Mandelli F, Gruppo Italiano Malattie Ematologiche dell'Adults: Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group. Ann Oncol; 2001 Feb;12(2):203-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute myeloid leukemia in patients previously diagnosed with breast cancer: experience of the GIMEMA group.
  • OBJECTIVE: To evaluate in a multicenter retrospective study, the clinical and laboratory characteristics and the outcome of patients with acute myeloid leukemia (sAML) previously diagnosed with breast cancer (BC) among an adult acute leukemia population.
  • PATIENTS AND METHODS: Between June 1992 and July 1996, 3934 new cases of adults with acute leukemia were recorded in GIMEMA Archive of Adult Acute Leukemia (2964 AML, 901 ALL, 69 acute leukemia expressing both myeloid and lymphoid surface markers).
  • RESULTS: Two hundred patients (5.1%) presented with a history of previous malignancy (21 of them were affected by ALL and 179 by AML).
  • The drugs most frequently employed were alkylating agents (18 patients), topoisomerase II inhibitors (9 patients), antimetabolites (20 patients) (CMF, CEF and MMM combinations).
  • Considering morphological features, FAB subtypes were 4 M0, 5 M1, 11 M2, 5 M3, 8 M4, 3 M5, and 1 M6.
  • It is noteworthy that chromosome 5 or 7 abnormalities (typically observed in those patients treated with alkylating agents) were present only in three cases.
  • Our results suggest that the risk of sAML after recovery from breast cancer is increasing due to the rise in the number of patients cured from breast cancer, and in the future could be a relevant problem for haematologists.

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11300325.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


Advertisement
4. Nagashima T, Izumi T, Muroi K, Miyasato A, Uchida M, Imagawa S, Komatsu N, Yoshida M, Hatake K, Miura Y, Ozawa K: [Two cases of acute myelogenous leukemia complicated with fatal gastrointestinal tract bleeding after treatment with idarubicin and cytarabine]. Gan To Kagaku Ryoho; 2000 Mar;27(3):487-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of acute myelogenous leukemia complicated with fatal gastrointestinal tract bleeding after treatment with idarubicin and cytarabine].
  • We describe herein two newly diagnosed patients with acute myelogenous leukemia (AML), who were treated twice with an idarubicin hydrochloride (IDR)-containing regimen as a response-orientated induction therapy.
  • The two patients were as follows: a 35-year-old male, FAB-M4, and a 47-year-old female, FAB-M0.
  • One died of sepsis, and the other of acute respiratory distress syndrome without a recovery in bone marrow.
  • [MeSH-major] Antibiotics, Antineoplastic / adverse effects. Gastrointestinal Hemorrhage / chemically induced. Idarubicin / adverse effects. Leukemia, Myeloid, Acute / drug therapy
  • [MeSH-minor] Adult. Bone Marrow / drug effects. Fatal Outcome. Female. Humans. Male. Middle Aged


5. Schaich M, Illmer T, Seitz G, Mohr B, Schäkel U, Beck JF, Ehninger G: The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia. Haematologica; 2001 May;86(5):470-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The prognostic value of Bcl-XL gene expression for remission induction is influenced by cytogenetics in adult acute myeloid leukemia.
  • So far expression studies of apoptosis-regulating genes on acute myeloid leukemia (AML) have mainly focused on Bcl-2 itself and most of them have not included other factors involved in drug resistance or apoptosis as parameters determining response to chemotherapy, disease progression and survival.
  • DESIGN AND METHODS: We therefore examined Bcl-2, Bcl-XL and Bax gene expression in 235 adult patients with de novo or secondary myeloid leukemia.
  • Bcl-2 expression correlated with FAB subtype M0 (p=0.03), Bax with M5b (p=0.02) and Bcl-XL with M6 (p=0.005).
  • Remarkably Bax was significantly less frequently expressed in de novo AML patients with high risk cytogenetics (p=0.007).
  • However, in the multivariate analysis regarding the group of de novo AML patients < or =60 years with intermediate risk cytogenetics, Bcl-XL expression was found to be an independent negative prognostic factor for response to induction therapy (p=0.04).
  • INTERPRETATION AND CONCLUSIONS: These data indicate that the prognostic value of Bcl-XL gene expression for treatment response in AML patients < or =60 years is dependent on cytogenetics.
  • [MeSH-major] Leukemia, Myeloid / diagnosis. Proto-Oncogene Proteins c-bcl-2 / genetics
  • [MeSH-minor] Acute Disease. Adult. Aged. Biomarkers. Cytogenetic Analysis. Gene Expression. Humans. Middle Aged. Prognosis. Proto-Oncogene Proteins / genetics. RNA, Messenger / metabolism. Remission Induction. bcl-2-Associated X Protein. bcl-X Protein

  • Genetic Alliance. consumer health - Acute Myeloid Leukemia, Adult.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11410409.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / BAX protein, human; 0 / BCL2L1 protein, human; 0 / Biomarkers; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 0 / bcl-2-Associated X Protein; 0 / bcl-X Protein
  •  go-up   go-down


6. Del Poeta G, Venditti A, Del Principe MI, Maurillo L, Buccisano F, Tamburini A, Cox MC, Franchi A, Bruno A, Mazzone C, Panetta P, Suppo G, Masi M, Amadori S: Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). Blood; 2003 Mar 15;101(6):2125-31
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML).
  • The inability to undergo apoptosis is a crucial mechanism of multidrug resistance in acute myeloid leukemia (AML), and the analysis of mitochondrial apoptotic proteins may represent a significant prognostic tool to predict outcome.
  • Bcl-2 and Bax oncoproteins were evaluated in 255 de novo AML patients (pts) by flow cytometry using an anti-bcl-2 monoclonal antibody (MoAb) and an anti-bax MoAb.
  • Lower bax/bcl-2 ratio was associated with French-American-British (FAB) M0-M1 classes (P =.000 01) and CD34 more than 20% (P <.000 01).
  • [MeSH-major] Apoptosis. Leukemia, Myeloid, Acute / mortality. Leukemia, Myeloid, Acute / pathology. Proto-Oncogene Proteins / analysis. Proto-Oncogene Proteins c-bcl-2 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antigens, CD34 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease-Free Survival. Drug Resistance, Multiple. Drug Resistance, Neoplasm. Flow Cytometry. Humans. Middle Aged. Mitochondria / chemistry. Prognosis. Proto-Oncogene Proteins c-kit / analysis. Regression Analysis. Remission Induction. Survival Rate. bcl-2-Associated X Protein

  • Genetic Alliance. consumer health - Acute Myelocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12424199.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / BAX protein, human; 0 / Proto-Oncogene Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / bcl-2-Associated X Protein; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


7. Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H: Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol; 2004 Feb;72(2):89-106
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies.
  • There is evidence to suggest, that those receptors (R) could play a role in leukemia with respect to cell differentiations and its regulation, prognosis, and pathobiology.
  • METHODS: We have studied the expression of CKR on mononuclear bone marrow (BM) cells of 89 patients with acute myeloid leukemia (AML) at first diagnosis, three patients at relapse or with persisting AML and eight healthy probands by fluorescence-activated cell sorting (FACS) analysis using directly fluorescein-conjugated antibodies: CD114 (hG-CSF-R), CD116 (hGM-CSF-R), CD117 (hSCF-R), CD123 (hIL-3-R), CD130 (gp130subunit), CD135 (hFL-R).
  • RESULTS: All investigated CKR were more frequently expressed in AML-samples than in healthy BM-samples, except CD130, which was only expressed on 5-6% of AML-blasts in all and with only one healthy BM-sample being CD130(+).
  • Within the French-American-British (FAB) types we observed a maturation- and lineage (granulocytic/monocytic)-committed expression profile.
  • Monocytic subtypes (FAB-type M4/M5) showed significantly more GM-CSF-R(+) (P = 0.001) and FL-R(+) (P = 0.001) and significantly less stem cell factor-R (SCF-R(+)) (P = 0.02) cases.
  • Highest proportions of G-CSF-R(+) blasts were observed in FAB-type M3.
  • In undifferentiated leukemias (FAB-type M1, M2) high amounts of SCF-R(+), IL-3-R(+), and FL-R(+) blasts could be detected.
  • FL-R was the only CKR, which was positive in FAB-type M0 (n = 2).
  • For clinical evaluation only patients treated by the AML-CG-protocol, were included (n = 53).
  • CONCLUSION: We can conclude, that CKR-expression in AML is maturation- and lineage-committed and the proportions of especially early acting CKR have influence on relapse-free survival probability of AML-patients, independently of the karyotype.
  • With respect to the individual CKR status the benefit of cytokines as priming agents, as agents to treat neutropenia or to influence the metabolism of chemotherapy can be discussed under new points of view.
  • [MeSH-major] Leukemia, Myeloid, Acute / immunology. Receptors, Cytokine / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Recurrence. Time Factors


8. Jenkins C, Hewamana S, Gilkes A, Neelakantan S, Crooks P, Mills K, Pepper C, Burnett A: Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia. Br J Haematol; 2008 Dec;143(5):661-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nuclear factor-kappaB as a potential therapeutic target for the novel cytotoxic agent LC-1 in acute myeloid leukaemia.
  • This study demonstrated the constitutive activation of NF-kappaB in human myeloid blasts and a clear correlation between NF-kappaB expression and in vitro cytoprotection.
  • High NF-kappaB expression was found in many of the poor prognostic acute myeloid leukaemia (AML) subtypes, such as French-American-British classification M0 and M7, and the poor cytogenetic risk group.
  • The in vitro effects of LC-1, a novel dimethylamino-parthenolide analogue, were assessed in 62 primary untreated AML samples.
  • LC-1 was found to be cytotoxic to AML cells in a dose-dependent manner, mediated through the induction of apoptosis.
  • The median drug concentration necessary to kill 50% of the cells was 4.5 micromol/l for AML cells, compared with 12.8 micromol/l for normal marrow cells.
  • LC-1 was shown to reduce the five individual human NF-kappaB Rel proteins in a dose-dependent manner.
  • Consequently, LC-1 treatment provides a proof of principle for the use of NF-kappaB inhibitors in the treatment of AML.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Leukemia, Myeloid, Acute / metabolism. NF-kappa B / antagonists & inhibitors. Sesquiterpenes / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Apoptosis. Cytotoxicity Tests, Immunologic. Electrophoretic Mobility Shift Assay. Enzyme-Linked Immunosorbent Assay / methods. Female. Humans. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Tumor Cells, Cultured. Young Adult

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036014.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / LC-1 compound; 0 / NF-kappa B; 0 / Sesquiterpenes
  •  go-up   go-down


9. Cellai C, Laurenzana A, Bianchi E, Sdelci S, Manfredini R, Vannucchi AM, Caporale R, Balliu M, Mannelli F, Ferrari S, Bosi A, Miniati D, Cocco PL, Veronneau S, Stankova J, Paoletti F: Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN. Exp Hematol; 2009 Oct;37(10):1176-1185.e21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mechanistic insight into WEB-2170-induced apoptosis in human acute myelogenous leukemia cells: the crucial role of PTEN.
  • OBJECTIVE: This study aimed to investigate the mechanisms of action of WEB-2170, an inverse agonist of platelet-activating factor receptor, capable of inducing apoptosis in human acute myelogenous leukemia (AML) cells.
  • MATERIAL AND METHODS: Gene expression profiling followed by cytofluorimetric, morphologic, and biologic analyses were used to monitor WEB-2170 effects in AML cell lines (ie, NB4, KG1, NB4-MR4, THP1, and U937) and blasts from patients with different AML (M0-M5) subtypes.
  • RESULTS: We have demonstrated that drug-mediated cytostasis/apoptosis in NB4 cells is characterized by upregulation of cyclin G2, p21/WAF1, NIX, TNF-alpha, and PTEN expression, and downregulation of cyclin D2 and BCL2 expression.
  • Finally, we show that PTEN silencing in NB4 cells by PTEN-specific small interfering RNA resulted in a significant reduction of drug-induced apoptosis.
  • CONCLUSION: We demonstrated that WEB-2170 is a powerful antileukemic agent with interesting translational opportunities to treat AML and described mechanisms of drug-induced intrinsic and extrinsic apoptosis both in AML cell lines and blasts from AML patients by addressing PTEN as the master regulator of the whole process.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Azepines / pharmacology. Leukemia, Myeloid / pathology. Neoplasm Proteins / physiology. PTEN Phosphohydrolase / physiology. Triazoles / pharmacology
  • [MeSH-minor] Acute Disease. Adult. Aged. Cell Line, Tumor / drug effects. Female. G0 Phase / drug effects. Gene Expression Profiling. Gene Expression Regulation, Leukemic / drug effects. Gene Expression Regulation, Leukemic / physiology. Humans. Male. Middle Aged. Neoplastic Stem Cells / drug effects. Neoplastic Stem Cells / pathology. Phosphorylation / drug effects. Polymerase Chain Reaction. Protein Processing, Post-Translational / drug effects. Protein Transport / drug effects. RNA Interference. RNA, Small Interfering / pharmacology. Young Adult


10. Centers for Disease Control and Prevention (CDC): Progressive vaccinia in a military smallpox vaccinee - United States, 2009. MMWR Morb Mortal Wkly Rep; 2009 May 22;58(19):532-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Progressive vaccinia (PV), previously known as vaccinia necrosum, vaccinia gangrenosum, or disseminated vaccinia, is a rare, often fatal adverse event after vaccination with smallpox vaccine, which is made from live vaccinia virus.
  • The service member had been newly diagnosed with acute mylegenous leukemia M0 (AML M0).
  • During evaluation for a chemotherapy-induced neutropenic fever, he was found to have an expanding and nonhealing painless vaccination site 6.5 weeks after receipt of smallpox vaccine.
  • To support future public health needs adequately, the estimated national supply of therapeutics and diagnostic resources required to care for smallpox vaccine adverse events should be reevaluated.
  • [MeSH-major] Smallpox Vaccine / adverse effects. Vaccinia / etiology
  • [MeSH-minor] Adult. Clostridium Infections. DNA, Viral / analysis. Disease Progression. Humans. Immunoglobulins, Intravenous / therapeutic use. Leukemia, Myeloid, Acute / drug therapy. Male. Military Personnel. Multiple Organ Failure. Pseudomonas Infections. United States

  • Genetic Alliance. consumer health - Smallpox.
  • MedlinePlus Health Information. consumer health - Smallpox.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19478722.001).
  • [ISSN] 1545-861X
  • [Journal-full-title] MMWR. Morbidity and mortality weekly report
  • [ISO-abbreviation] MMWR Morb. Mortal. Wkly. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / Immunoglobulins, Intravenous; 0 / Smallpox Vaccine
  •  go-up   go-down


11. Möhle R, Schittenhelm M, Failenschmid C, Bautz F, Kratz-Albers K, Serve H, Brugger W, Kanz L: Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia. Br J Haematol; 2000 Sep;110(3):563-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional response of leukaemic blasts to stromal cell-derived factor-1 correlates with preferential expression of the chemokine receptor CXCR4 in acute myelomonocytic and lymphoblastic leukaemia.
  • We analysed SDF-1-induced intracellular calcium fluxes in leukaemic blasts from the peripheral blood of patients with newly diagnosed acute myeloid leukaemia (AML) and lymphoblastic leukaemia (B-lineage ALL), determined the effect of BM stromal cell-conditioned medium on in vitro transendothelial migration (TM) and measured expression of the SDF-1 receptor, CXCR4, by flow cytometry.
  • AML FAB M1/2 blasts did not show calcium fluxes and TM was not stimulated.
  • In myelomonocytic AML (M4/5), however, SDF-1 induced significant calcium fluxes and TM was increased twofold by the conditioned medium.
  • Accordingly, expression of CXCR4 was low in undifferentiated (M0) AML, myeloid (M1/2) AML and erythroid (M6) AML, but high [mean fluorescence (MF) > 50] in promyelocytic (M3) AML, myelomonocytic (M4/5) AML and B-lineage ALL.
  • We conclude that, in AML, SDF-1 is preferentially active in myelomonocytic blasts as a result of differentiation-related expression of CXCR4.
  • [MeSH-major] Chemokines, CXC / pharmacology. Leukemia, Myelomonocytic, Acute / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Receptors, CXCR4 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Calcium / metabolism. Cell Movement / drug effects. Cells, Cultured. Chemokine CXCL12. Female. Humans. Male. Middle Aged

  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10997965.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / CXCL12 protein, human; 0 / Chemokine CXCL12; 0 / Chemokines, CXC; 0 / Receptors, CXCR4; SY7Q814VUP / Calcium
  •  go-up   go-down


12. Fujisaki H, Takai K, Akihisa S, Tokimasa S, Matsuda Y, Ohta H, Osugi Y, Kim JY, Hosoi G, Sako M, Hara J: Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation. Int J Hematol; 2002 Jan;75(1):72-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a monosomy 7 leukemia cell line, MONO-7, with a ras gene mutation.
  • A monosomy 7 leukemia cell line, designated MONO-7, was established from the peripheral blood of a patient with monosomy 7 acute myelocytic leukemia (French-American-British classification M0).
  • [MeSH-major] Chromosomes, Human, Pair 7. Genes, ras. Leukemia, Myeloid / pathology. Leukemia-Lymphoma, Adult T-Cell / pathology. Monosomy. Tumor Cells, Cultured
  • [MeSH-minor] Acute Disease. Animals. Cell Division / drug effects. Cell Lineage. Child, Preschool. DNA Mutational Analysis. DNA, Neoplasm / genetics. Disease Progression. Gene Rearrangement. Granulocyte-Macrophage Colony-Stimulating Factor / pharmacology. Humans. Immunophenotyping. Interleukin-3 / pharmacology. Karyotyping. Male. Mice. Mice, Inbred NOD. Mice, SCID. Neoplasm Transplantation. Recombinant Proteins / pharmacology

  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cellosaurus - a cell line knowledge resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 1989 Jan;73(1):263-70 [2910364.001]
  • [Cites] Blood. 1991 Feb 1;77(3):594-8 [1991170.001]
  • [Cites] Br J Haematol. 1988 Sep;70(1):55-62 [3179229.001]
  • [Cites] Blood. 1992 Mar 15;79(6):1501-10 [1347709.001]
  • [Cites] Br J Haematol. 1991 Oct;79(2):152-5 [1958471.001]
  • [Cites] Br J Haematol. 1981 Oct;49(2):235-49 [6945867.001]
  • [Cites] Exp Hematol. 1999 May;27(5):826-33 [10340398.001]
  • [Cites] Cancer Genet Cytogenet. 1981 Nov;4(3):197-214 [7317873.001]
  • [Cites] Leuk Res. 1987;11(8):705-9 [3626612.001]
  • [Cites] Blood. 1995 Apr 15;85(8):1985-99 [7718870.001]
  • [Cites] Br J Haematol. 1985 Nov;61(3):531-9 [3864487.001]
  • [Cites] Leukemia. 1994 May;8(5):903-8 [8182949.001]
  • [Cites] Blood. 1992 Jul 1;80(1):217-24 [1611087.001]
  • [Cites] Blood. 1994 Apr 15;83(8):2248-54 [8161790.001]
  • [Cites] Eur J Haematol. 1991 Jul;47(1):17-27 [1868912.001]
  • [Cites] Blood. 1988 Feb;71(2):403-14 [3337904.001]
  • [Cites] Blood. 1982 Aug;60(2):404-11 [7093525.001]
  • [Cites] Leukemia. 1993 Sep;7(9):1315-23 [8371581.001]
  • [Cites] Br J Haematol. 1986 Dec;64(4):842-4 [3801325.001]
  • [Cites] Birth Defects Orig Artic Ser. 1985;21(1):1-117 [4041569.001]
  • [Cites] Am J Pediatr Hematol Oncol. 1990 Spring;12(1):63-70 [2309981.001]
  • [Cites] Blood. 1994 Oct 1;84(7):2380-1 [7522628.001]
  • [Cites] J Clin Oncol. 1986 Mar;4(3):325-45 [3950675.001]
  • [Cites] Med Pediatr Oncol. 1988;16(4):227-32 [3419390.001]
  • [Cites] Br J Haematol. 1986 Nov;64(3):425-33 [3466639.001]
  • [Cites] Leuk Res. 1992 Aug;16(8):789-96 [1528067.001]
  • (PMID = 11843295.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Interleukin-3; 0 / Recombinant Proteins; 83869-56-1 / Granulocyte-Macrophage Colony-Stimulating Factor
  •  go-up   go-down


13. Yoshida K, Kusumoto S, Sugahara Y, Yagasaki F, Sakata T, Kawai N, Matsuda A, Suzuki T, Hirashima K, Kayano H, Bessho M: [CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion]. Rinsho Ketsueki; 2001 Aug;42(8):644-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CD7(+) acute myeloid leukemia (M0) associated with a mediastinal bulky mass lesion].
  • His symptoms did not improve, despite administration of antibiotics and nonsteroidal anti-inflammatory drugs.
  • We diagnosed the patient as having CD7 (+) acute myeloid leukemia (AML) (M0) with a bulky mediastinal mass based on the surface marker analysis, although the clinical features resembled myeloid/NK precursor acute leukemia.
  • [MeSH-major] Antigens, CD7 / analysis. Leukemia, Myeloid, Acute / diagnosis. Mediastinal Neoplasms / diagnosis. Neoplasms, Multiple Primary
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cytarabine / administration & dosage. Diagnosis, Differential. Hematopoietic Stem Cell Transplantation. Humans. Idarubicin / administration & dosage. Male. Remission Induction

  • Genetic Alliance. consumer health - Leukemia, Myeloid.
  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • Hazardous Substances Data Bank. CYTARABINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11579505.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, CD7; 04079A1RDZ / Cytarabine; ZRP63D75JW / Idarubicin
  •  go-up   go-down






Advertisement